BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1493082)

  • 1. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.
    Brockmöller J; Köchling J; Weber W; Looby M; Roots I; Neumayer HH
    Br J Clin Pharmacol; 1992 Dec; 34(6):499-508. PubMed ID: 1493082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
    Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Chung WW; Leung CB; Chan K; Lai KN
    Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin response and route of administration.
    Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns.
    Melo AM; Costa MT; Porta V; Vaz FA
    J Matern Fetal Neonatal Med; 2005 Jan; 17(1):55-8. PubMed ID: 15804788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).
    Muirhead N; Laupacis A; Wong C
    Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and haematological effects of erythropoietin in horses.
    Jaussaud P; Audran M; Gareau RL; Souillard A; Chavanet I
    Vet Res; 1994; 25(6):568-73. PubMed ID: 7889038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
    Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
    Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs.
    Randolph JF; Stokol T; Scarlett JM; MacLeod JN
    Am J Vet Res; 1999 May; 60(5):636-42. PubMed ID: 10328437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
    Salmonson T
    Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD.
    Eidemak I; Friedberg MO; Ladefoged SD; Løkkegaard H; Pedersen E; Skielboe M
    Nephrol Dial Transplant; 1992; 7(6):526-9. PubMed ID: 1320232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
    Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.